Outcome of hydroxycarbamide therapy in children, adolescents and young adults (CAYAs) with sickle cell disease in a pediatric hematology center

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

DRKS

Registry ID

DRKS00028552

Enrollment

Registered

2022-03-12

Start date

2022-08-05

Completion date

Unknown

Last updated

2025-10-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

D57

Interventions

Group 1: 1. identification of sickle cell patients of CAYA age who were/are treated with the drug hydroxycarbamide in the Department of Pediatric Hematology and Oncology at the University Medical Cent

Eligibility

Sex/Gender

All

Age

No minimum to 30 Years

Inclusion criteria

Inclusion criteria: Informed consent Diagnosis of sickle cell disease and therapy with hydroxycarbamide

Exclusion criteria

Exclusion criteria: Absence of informed consent

Design outcomes

Primary

Measure	Time frame
Hydroxycarbamide therapy leads to a decrease in the frequency of pain crises (defined as pain in different localizations requiring the use of analgesics) and a decrease in days with pain per year (measured with an age-adjusted pain scale) in CAYAs.	—

Secondary

Measure	Time frame
2.1 Under hydroxycarbamide therapy, CAYAs show an increase in HbF level and MCV. 2.2 Under hydroxycarbamide therapy, known hemolysis parameters decrease in CAYAs.	—

Countries

Germany

Contacts

Public ContactAlexander Puzik

Kinder- und Jugendklinik des Universitätsklinikums Freiburg, Klink für pädiatrische Hämatologie und Onkologie

alexander.puzik@uniklinik-freiburg.de+49-(0)761-270-43000

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026